Under Robert A. Michael’s leadership, AbbVie strengthened its innovation pipeline with multiple regulatory approvals and strategic R&D advancements, including Rinvoq’s new GCA indication and FDA’s accelerated approval for Emrelis. Combined with robust sales from immunology and neuroscience portfolios, AbbVie continues to solidify its market position.

AbbVie Inc. reported Q2 2025 net revenues of $15.42 billion, reflecting a 6.6% year-over-year increase on a reported basis and 6.5% on an operational basis. The company delivered an adjusted diluted EPS of $2.97 (up 12.1%), despite a GAAP diluted EPS of $0.52, impacted by $0.42 per share of acquired IPR&D and milestone expenses.

The strong quarter was driven by the immunology and neuroscience portfolios, particularly Skyrizi (up 62%), Rinvoq (up 41%), and Vraylar (up 16%), alongside significant gains in Botox Therapeutic and migraine treatments Ubrelvy and Qulipta. Oncology showed modest growth of 2.6%, while aesthetics faced an 8.1% decline.

AbbVie also advanced its pipeline with regulatory approvals, including Rinvoq’s new indication for giant cell arteritis, FDA’s accelerated approval of Emrelis for advanced NSCLC, and promising late-stage trial data for Qulipta and Venclexta combinations.

Commenting on the results, Robert A. Michael, AbbVie’s Chairman and CEO, said:
"AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data, and strategic investments in external innovation. Entering the second half of the year, we have substantial momentum and are once again raising our full-year outlook."

The company raised its FY2025 adjusted EPS guidance to $11.88 – $12.08, reinforcing confidence in sustained growth across its core therapeutic areas.

Click here to read more